Media coverage about Incyte (NASDAQ:INCY) has been trending somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Incyte earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.8574539121864 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Accern’s rankings:
- Hematologic Malignancy Patient Simulations: Diagnosis and Treatment (medscape.org)
- $411.33 Million in Sales Expected for Incyte Corporation (INCY) This Quarter (americanbankingnews.com)
- Worth Watching Stock’s Buzzers: Incyte Corporation, (NASDAQ: INCY), General Motors Company, (NYSE: GM … – Stocks In The News (press release) (tradingnewsnow.com)
- FY2021 EPS Estimates for Incyte Corporation (INCY) Lowered by Gabelli (americanbankingnews.com)
- Before and After: Patient Cases in Onychomycosis (medscape.org)
Shares of Incyte (INCY) traded down $0.92 on Monday, hitting $97.86. The stock had a trading volume of 1,318,292 shares, compared to its average volume of 1,927,243. Incyte has a 52 week low of $96.60 and a 52 week high of $153.15. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The company had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. During the same period last year, the company earned $0.19 earnings per share. The firm’s revenue was up 41.6% compared to the same quarter last year. research analysts anticipate that Incyte will post -1.33 EPS for the current fiscal year.
Several equities analysts have commented on INCY shares. J P Morgan Chase & Co set a $149.00 target price on Incyte and gave the company a “buy” rating in a research report on Tuesday, August 1st. Argus reiterated a “buy” rating and issued a $150.00 target price on shares of Incyte in a research report on Wednesday, September 13th. Jefferies Group LLC reiterated a “buy” rating on shares of Incyte in a research report on Friday, October 6th. Goldman Sachs Group Inc started coverage on Incyte in a research report on Friday, October 6th. They issued a “buy” rating and a $160.00 target price for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating and issued a $135.00 target price on shares of Incyte in a research report on Sunday, September 10th. Seven equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $145.65.
In other Incyte news, EVP Steven H. Stein sold 2,111 shares of Incyte stock in a transaction that occurred on Tuesday, August 29th. The stock was sold at an average price of $125.00, for a total value of $263,875.00. Following the completion of the sale, the executive vice president now directly owns 18,687 shares in the company, valued at $2,335,875. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Herve Hoppenot sold 70,502 shares of Incyte stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 130,569 shares of company stock valued at $15,652,970. 17.70% of the stock is currently owned by corporate insiders.
WARNING: This piece of content was reported by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/11/28/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-incyte-incy-stock-price.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.